Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Phoenix Financial Ltd.

Phoenix Financial Ltd. lessened its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 9.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,309 shares of the medical research company’s stock after selling 4,524 shares during the period. Phoenix Financial Ltd.’s holdings in Edwards Lifesciences were worth $3,280,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Edwards Lifesciences by 10.4% in the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock valued at $5,117,845,000 after purchasing an additional 6,537,494 shares in the last quarter. Wellington Management Group LLP boosted its stake in Edwards Lifesciences by 5.3% during the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company’s stock worth $2,458,601,000 after buying an additional 1,678,154 shares during the last quarter. Geode Capital Management LLC grew its holdings in Edwards Lifesciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company’s stock valued at $1,007,520,000 after buying an additional 126,194 shares in the last quarter. Fisher Asset Management LLC increased its stake in shares of Edwards Lifesciences by 7.7% in the 4th quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock worth $723,664,000 after acquiring an additional 696,965 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth $610,895,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares of the company’s stock, valued at $4,613,628.24. This represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,853 shares of company stock worth $4,534,247 over the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 2.3 %

EW stock opened at $68.26 on Friday. The company’s 50 day moving average price is $71.36 and its 200 day moving average price is $70.67. The firm has a market capitalization of $40.13 billion, a price-to-earnings ratio of 9.79, a PEG ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on EW shares. Morgan Stanley upped their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Evercore ISI reduced their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 12th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price objective for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Finally, Canaccord Genuity Group lifted their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.